Cancer Investigation

eISSN: 1532-4192pISSN: 0735-7907

Journal formatting to fit the target journal guidelines

Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!

Aims and Scope

Cancer Investigation is a peer-reviewed medical journal in the field of basic and clinical oncology. The editor in chief is Gary Lyman. It is currently indexed for MEDLINE.

Key Metrics

CiteScore
3.2
H-Index
90
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.61
8
Time to Publish
time-to-publish View Chart
9  Mo

Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
  • Publisher
    TAYLOR & FRANCIS INC
  • Language
    English
  • Frequency
    Monthly
General Details
View less

Ready to spotlight your research findings?

Impress peers and journals alike with a concise, visual summary of your work.

Meets Top Publisher Standards: Essential for leading journals like Elsevier.
Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.
Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
Learn more 3000+ graphical abstracts produced with 4.8/5 customer rating
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 6%
4-6 29%
7-9 21%
>9 44%

Topics Covered

Cancer
Lung cancer
Sinonasal undifferentiated carcinoma
Overall survival
Fibrinogen
Hepatocellular carcinoma
Tumor microenvironment
Prostate cancer
Breast cancer
Magnetic resonance imaging
Radiation
Transarterial Radioembolization
Colorectal cancer
Prostatectomy
Type 2 diabetes
Self-efficacy
Mitochondrial DNA
Cancer immunotherapy
Clinical trial
Absolute lymphocyte count

Recently Published Papers

Year-wise Publication

FAQs

Since when has Cancer Investigation been publishing? Faqs

The Cancer Investigation has been publishing since 1983 till date.

How frequently is the Cancer Investigation published? Faqs

Cancer Investigation is published Monthly.

What is the H-index. SNIP score, Citescore and SJR of Cancer Investigation? Faqs

Cancer Investigation has a H-index score of 90, Citescore of 3.2, SNIP score of 0.61, & SJR of Q2

Who is the publisher of Cancer Investigation? Faqs

The publisher of Cancer Investigation is TAYLOR & FRANCIS INC.

Where can I find a journal's aims and scope of Cancer Investigation? Faqs

For the Cancer Investigation's Aims and Scope, please refer to the section above on the page.

How can I view the journal metrics of Cancer Investigation on editage? Faqs

For the Cancer Investigation metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Cancer Investigation? Faqs

The eISSN number is 1532-4192 and pISSN number is 0735-7907 for Cancer Investigation.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Cancer, Lung cancer, Sinonasal undifferentiated carcinoma, Overall survival, Fibrinogen, Hepatocellular carcinoma, Tumor microenvironment, Prostate cancer, Breast cancer, Magnetic resonance imaging, Radiation, Transarterial Radioembolization, Colorectal cancer, Prostatectomy, Type 2 diabetes, Self-efficacy, Mitochondrial DNA, Cancer immunotherapy, Clinical trial, Absolute lymphocyte count.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.